Home » REJECTION OF SLEEP DRUG CAUSES SHARES OF DOV TO NOSE DIVE
REJECTION OF SLEEP DRUG CAUSES SHARES OF DOV TO NOSE DIVE
Shares of three pharmaceutical companies declined after indiplon, a sleeping medication, failed to win federal approval Tuesday. Shares of Neurocrine Biosciences Inc., which submitted the application, declined 56 percent to close at $23.86, while Pfizer, Neurocrine's marketing and development partner, saw its stock drop 2 cents to close at $24.87.
North Jersey Media Group
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May